HMOX1 and triple-negative breast carcinoma: Recently, the molecules of luteolin have been described as a potential agent in triple-negative breast cancer (MDA-MB-231 cell line) treatments by suppressing the protein expressions of nuclear erythroid factor 2 (Nrf2), heme oxygenase 1 (HO-1), and Crypto-1, which contribute significantly and critically to the functioning of cancer stem cells [36].